Bosentan increases myocardial perfusion and function in systemic sclerosis: A magnetic resonance imaging and Tissue-Doppler echography study

Journal of Rheumatology

Volumn 33, Issue 12, 2006, Pages 2464-2469

  Allanore, Yannick ^a,d   Meune, Christophe ^b   Vignaux, Olivier ^c   Weber, Simon ^b   Legmann, Paul ^c   Kahan, Andre ^a  

^a Service de Rhumatologie A   (France)

^b Service de Cardiologie   (Switzerland)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Service de Rhumatologie A ^*  (France)

Author keywords

Bosentan; Myocardium magnetic resonance imaging; Systemic sclerosis; Tissue Doppler echocardiography

Indexed keywords

BOSENTAN; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLE; DOPPLER ECHOGRAPHY; DRUG DOSE TITRATION; FEMALE; HEART FAILURE; HEART FUNCTION; HEART MUSCLE PERFUSION; HUMAN; LUNG ARTERY PRESSURE; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SHORT COURSE THERAPY; SYSTEMIC SCLEROSIS; SYSTOLE; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CORONARY CIRCULATION; ECHOCARDIOGRAPHY, DOPPLER; HEART; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MYOCARDIAL CONTRACTION; SCLERODERMA, SYSTEMIC; SULFONAMIDES;

EID: 33846105414     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Follansbee WP, Curtiss EI, Medsger TA Jr, et al. Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma. N Engl J Med 1984;310:142-8.
2. Kahan A, Devaux JY, Amor B, et al. Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis. N Engl J Med 1986;314:1397-402.
3. Candell-Ria J, Armadans-Gil L, Simeón CP. Comprehensive noninvasive assessment of cardiac involvement in limited systemic sclerosis. Arthritis Rheum 1996;39:1138-45.
4. Clements PJ, Lachenbruch PA, Furst DE, Paulus HE, Sterz MG. Cardiac score. A semiquantitative measure of cardiac involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum 1991;34:1371-80.
5. Meune C, Allanore Y, Devaux JY, et al. High prevalence of right ventricular systolic dysfunction in early systemic sclerosis. J Rheumatol 2004,31:1941-5.
6. Kahan A, Devaux JY, Amor B, et al. The effect of captopril on thallium 201 myocardial perfusion in systemic sclerosis. Clin Pharmacol Ther 1990;47:483-9.
7. Duboc D, Kahan A, Maziere B, et al. The effect of nifedipine on myocardial perfusion and metabolism in systemic sclerosis. A positron emission tomographic study. Arthritis Rheum 1991;34:198-203.
8. Kahan A, Devaux JY, Amor B, et al. Pharmacodynamic effect of nicardipine on left ventricular function in systemic sclerosis. J Cardiovasc Pharmacol 1990;15:249-53.
9. Lima JA, Desai MY. Cardiovascular magnetic resonance imaging: current and emerging applications. J Am Coll Cardiol 2004;44:1164-71.
10. Vignaux O, Allanore Y, Meune C, et al. Evaluation of nifedipine efficacy on myocardial perfusion and contractility using cardiac magnetic resonance imaging and tissue Doppler echocardiography in systemic sclerosis. Ann Rheum Dis 2005;64:1268-73.
11. Greenberg NL, Firstenberg MS, Castro PL, et al. Doppler-derived myocardial systolic strain rate is a strong index of left ventricular contractility. Circulation 2002;105:99-105.
12. Meune C, Allanore Y, Pascal O, et al. Myocardial contractility is early affected in systemic sclerosis: a tissue Doppler echocardiography study. Eur J Echocardiogr 2005;6:351-7.
13. Kahaleh MB. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma: enhanced production and profibrotic action. Arthritis Rheum 1991;34:978-83.
14. Mayes MD. Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum 2003;48:1190-9.
15. Kim NHS, Rubin LJ. Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension. J Cardiovasc Pharmacol Therapeut 2002;7:9-19.
16. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
17. Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985-93.
18. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
19. Valentini G, Medsger TA, Silman AJ, Bombardieri S. The assessment of the patient with systemic sclerosis. Clin Exp Rheum 2003;21 Suppl 29:S1-S56.
20. Matucci Cerinic M, Kahaleh MB. Beauty and the beast. The nitric oxide paradox in systemic sclerosis. Rheumatology Oxford 2002;41:843-7.
21. Viswamitra S, Higgins CB, Meacham DF, Mehta JL. Magnetic resonance imaging in myocardial ischemia. Curr Opin Cardiol 2004;19:510-6.
22. Panting JR, Gatehouse PD, Yang GZ, et al. Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging. N Engl J Med 2002;346:1948-53.
23. Pellerin D, Sharma R, Elliott P, Veyrat C. Tissue Doppler, strain, and strain rate echocardiography for the assessment of left and right systolic ventricular function. Heart 2003;89 Suppl 3:9-17.
24. Meune C, Pascal O, Becane HM, et al. Reliable detection of early myocardial dysfunction by tissue doppler echocardiography in Becker's muscular dystrophy. Heart 2004;98:947-8.
25. Packer M, McMurray J, Massie BM, et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail 2005;11:12-20.
26. Onishi K, Ohno M, Little WC, Cheng CP. Endogenous endothelin-1 depresses left ventricular systolic and diastolic performance in congestive heart failure. J Pharmacol Exp Ther 1999;288:1214-22.
27. Fern C, Valentini G, Cozzi F, et al. Systemic Sclerosis Study Group of the Italian Society of Rheumatology [SIR-GSSSc]. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine Baltimore 2002;81:139-53.
28. Hegedus I, Czirjak L. Left ventricular wall motion abnormalities in 80 patients with systemic sclerosis. Clin Rheumatol 1995;14:161-4.